Oruka Therapeutics
ORKA
14 hedge funds and large institutions have $1.46M invested in Oruka Therapeutics in 2014 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 4 closing their positions.
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
27% more funds holding
Funds holding: 11 → 14 (+3)
5% less capital invested
Capital invested by funds: $1.54M → $1.46M (-$83K)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SKK
Shepherd Kaplan Krochuk
Boston,
Massachusetts
|
+$323K |
| 2 |
California Public Employees Retirement System
Sacramento,
California
|
+$88.4K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$27.9K |
| 4 |
Goldman Sachs
New York
|
+$23.3K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$20.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$133K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
-$37.2K |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
-$30.2K |
| 4 |
RCM
Rotella Capital Management
Bellevue,
Washington
|
-$24K |
| 5 |
AL
Airain Ltd
St. Peter Port,
Guernsey
|
-$22K |
ORKA Hedge Fund Activity: Q2 2014 in Review
14 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q2 2014, worth a combined $1.46M — down 5.4% from $1.54M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ORKA positions and 4 closed out — a net gain of 3 holders — while 2 added to existing stakes and 3 trimmed.
The largest buyer was Shepherd Kaplan Krochuk, opening a new position worth an estimated $323K. The largest seller was Morgan Stanley, exiting entirely with an estimated $133K sold.
- 14 institutional investors held Oruka Therapeutics (ORKA) as of Q2 2014, up from 11 in Q1 2014.
- Funds reported $1.46M of Oruka Therapeutics stock for Q2 2014, down 5.4% quarter-over-quarter.
- 7 funds opened new Oruka Therapeutics positions in Q2 2014 and 4 closed out, a net change of +3 holders.
- The largest Oruka Therapeutics buyer in Q2 2014 was Shepherd Kaplan Krochuk, an estimated $323K added.
- The largest Oruka Therapeutics seller in Q2 2014 was Morgan Stanley, an estimated $133K sold.
Based on aggregated 13F filings for Q2 2014.